Some studies have shown additive effects by combining KRASG12C inhibitors with an anti-EGFR antibody to prevent reactivation of the RAS-MAPK pathway, which has been identified as a predominant mechanism of resistance to KRASG12C inhibitors in CRC.29 Combined blockade of KRASG12C and EGFR can overcome this adaptive resistance reported in both in vitro and in vivo studies.29 Current evidence suggests consistent improvements in ORR with combination therapies across KRASG12C inhibitors,23,30,31 while PFS and OS data remain less conclusive. This evidence concerns the gene EGFR and colorectal carcinoma.